These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 30545923

  • 21. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
    Wehmeyer J, Zaiss M, Losem C, Schmitz S, Niemeier B, Harde J, Hannig CV, Harich HD, Müller J, Klausmann M, Tessen HW, Potthoff K.
    Eur J Haematol; 2018 Dec; 101(6):766-773. PubMed ID: 30091166
    [Abstract] [Full Text] [Related]

  • 22. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
    Bewersdorf JP, Stahl M, Zeidan AM.
    Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
    [Abstract] [Full Text] [Related]

  • 23. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R, Connock M, Tubeuf S, Round J, Fry-Smith A, Hyde C, Greenheld W.
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [Abstract] [Full Text] [Related]

  • 24. Azacitidine-eligibility in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia: a registry-based study.
    Durairaj S, Keenan N, Hyslop A, Groves MJ, Bowen DT, Tauro S.
    Br J Haematol; 2013 Apr; 161(2):280-2. PubMed ID: 23294041
    [No Abstract] [Full Text] [Related]

  • 25. Azacitidine for the treatment of relapsed and refractory AML in older patients.
    Itzykson R, Thépot S, Berthon C, Delaunay J, Bouscary D, Cluzeau T, Turlure P, Prébet T, Dartigeas C, Marolleau JP, Recher C, Plantier I, Stamatoullas A, Devidas A, Taksin AL, Guièze R, Caillot D, Vey N, Adès L, Ifrah N, Dombret H, Fenaux P, Gardin C.
    Leuk Res; 2015 Feb; 39(2):124-30. PubMed ID: 25524177
    [Abstract] [Full Text] [Related]

  • 26. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
    Alhan C, Westers TM, van der Helm LH, Eeltink C, Huls G, Witte BI, Buchi F, Santini V, Ossenkoppele GJ, van de Loosdrecht AA.
    Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
    [Abstract] [Full Text] [Related]

  • 27. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.
    Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List AF, Maciejewski JP.
    Blood; 2012 Dec 13; 120(25):4945-51. PubMed ID: 22915641
    [Abstract] [Full Text] [Related]

  • 28. A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes.
    Mongiorgi S, De Stefano A, Ratti S, Indio V, Astolfi A, Casalin I, Pellagatti A, Paolini S, Parisi S, Cavo M, Pession A, McCubrey JA, Suh PG, Manzoli L, Boultwood J, Finelli C, Cocco L, Follo MY.
    Clin Epigenetics; 2023 Feb 20; 15(1):27. PubMed ID: 36803590
    [Abstract] [Full Text] [Related]

  • 29. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
    Seymour JF, Döhner H, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Del Castillo TB, Al-Ali HK, Falantes J, Stone RM, Minden MD, Weaver J, Songer S, Beach CL, Dombret H.
    BMC Cancer; 2017 Dec 14; 17(1):852. PubMed ID: 29241450
    [Abstract] [Full Text] [Related]

  • 30. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
    Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR.
    J Clin Oncol; 2010 Feb 01; 28(4):562-9. PubMed ID: 20026804
    [Abstract] [Full Text] [Related]

  • 31. An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia.
    Solly F, Koering C, Mohamed AM, Maucort-Boulch D, Robert G, Auberger P, Flandrin-Gresta P, Adès L, Fenaux P, Kosmider O, Tavernier-Tardy E, Cornillon J, Guyotat D, Campos L, Mortreux F, Wattel E.
    Clin Cancer Res; 2017 Jun 15; 23(12):3025-3034. PubMed ID: 27881579
    [Abstract] [Full Text] [Related]

  • 32. Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities.
    Wanquet A, Prebet T, Berthon C, Sebert M, Roux C, Kulasekararaj A, Micol JB, Esterni B, Itzykson R, Thepot S, Recher C, Delaunay J, Dreyfus F, Mufti G, Fenaux P, Vey N.
    Am J Hematol; 2015 Oct 15; 90(10):859-63. PubMed ID: 26113240
    [Abstract] [Full Text] [Related]

  • 33. The geriatric nutritional risk index predicts the early death and survival in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.
    Nishiyama-Fujita Y, Nakazato T, Kamiya T, Mizuno K, Ito C, Ogura S, Sakurai A, Tanigawa T, Akimoto M, Aisa Y.
    Hematol Oncol; 2020 Oct 15; 38(4):611-613. PubMed ID: 32515069
    [No Abstract] [Full Text] [Related]

  • 34. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
    Duong VH, Bhatnagar B, Zandberg DP, Vannorsdall EJ, Tidwell ML, Chen Q, Baer MR.
    Leuk Lymphoma; 2015 Jun 15; 56(6):1718-22. PubMed ID: 25263320
    [Abstract] [Full Text] [Related]

  • 35. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
    Abaza YM, Kadia TM, Jabbour EJ, Konopleva MY, Borthakur G, Ferrajoli A, Estrov Z, Wierda WG, Alfonso A, Chong TH, Chuah C, Koh LP, Goh BC, Chang JE, Durkes DE, Foudray MC, Kantarjian HM, Dong XQ, Garcia-Manero G.
    Cancer; 2017 Dec 15; 123(24):4851-4859. PubMed ID: 28841236
    [Abstract] [Full Text] [Related]

  • 36. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.
    Sekeres MA, List AF, Cuthbertson D, Paquette R, Ganetzky R, Latham D, Paulic K, Afable M, Saba HI, Loughran TP, Maciejewski JP.
    J Clin Oncol; 2010 May 01; 28(13):2253-8. PubMed ID: 20354132
    [Abstract] [Full Text] [Related]

  • 37. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.
    Mittelman M, Filanovsky K, Ofran Y, Rosenbaum H, Raanani P, Braester A, Goldschmidt N, Kirgner I, Herishanu Y, Perri C, Ellis M, Oster HS, Israel Myelodysplastic Syndrome Working Group (MDS-WG).
    Ann Hematol; 2016 Oct 01; 95(11):1811-8. PubMed ID: 27546027
    [Abstract] [Full Text] [Related]

  • 38. Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.
    Ossenkoppele GJ, Breems DA, Stuessi G, van Norden Y, Bargetzi M, Biemond BJ, A von dem Borne P, Chalandon Y, Cloos J, Deeren D, Fehr M, Gjertsen B, Graux C, Huls G, Janssen JJJW, Jaspers A, Jongen-Lavrencic M, de Jongh E, Klein SK, van der Klift M, van Marwijk Kooy M, Maertens J, Michaux L, van der Poel MWM, van Rhenen A, Tick L, Valk P, Vekemans MC, van der Velden WJFM, de Weerdt O, Pabst T, Manz M, Löwenberg B, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK).
    Leukemia; 2020 Jul 01; 34(7):1751-1759. PubMed ID: 32020044
    [Abstract] [Full Text] [Related]

  • 39. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
    Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ.
    Lancet Oncol; 2017 Oct 01; 18(10):1317-1326. PubMed ID: 28844816
    [Abstract] [Full Text] [Related]

  • 40. A limited number of 5-azacitidine cycles can be effective treatment in MDS.
    Müller-Thomas C, Schuster T, Peschel C, Götze KS.
    Ann Hematol; 2009 Mar 01; 88(3):213-9. PubMed ID: 18696067
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.